<DOC>
	<DOCNO>NCT00117728</DOCNO>
	<brief_summary>This study design test sequential protease-inhibitor ( PI ) - / nevirapine ( NVP ) -based regimen effective treatment HIV-infected child previous NVP exposure occur part program prevent mother-to-child transmission ( pMTCT ) .</brief_summary>
	<brief_title>Pediatric Nevirapine Resistance Study</brief_title>
	<detailed_description>The wide use NVP pMTCT-prophylaxis may result resistance NNRTI concomitantly limit use drug treatment HIV-infected child . To avoid restrict treatment option child , desirable preserve NVP pMTCT first line treatment . This study therefore test whether resistance-caused treatment failure HIV-infected previously NVP-exposed child avoid NVP treatment precede initial PI-based regimen . Comparison : HIV-infected child less 24 month age , expose pMTCT regimen include NVP achieve maintain viral suppression least 3 month PI-based regimen randomize one two group : ( 1 ) continue PI-containing regimen ( 2 ) switch PI-containing regimen onto NVP-containing regimen . The study outcome proportion two group complete virologic suppression 6 month randomization .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<criteria>NVPexposure part pMTCTprophylaxis around delivery HIVpositive Eligible treatment Plans stay area next 6 month Already antiretroviral treatment History toxicity perinatal NVP Grade 3 great elevation liver function test Being treat severe acute opportunistic infection tumor</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>24 Months</maximum_age>
	<verification_date>January 2006</verification_date>
	<keyword>Non-nucleoside reverse transcriptase inhibitor</keyword>
	<keyword>Drug Resistance</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>